TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37703908

Group type: COMPARATOR
Intervention: Ciclosporin (2-3 mg/kg before transplantation and 3 mg/kg twice per day from postoperative day 1)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.05-0.1 mg/kg before transplantation and 0.1-0.2 mg/kg from postoperative day 1)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 249

Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 249
Study: 37703948

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) with the FlowTriever System
Number of subjects: 550

Group type: COMPARATOR
Intervention: Catheter-directed thrombolysis (CDT)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 550
Study: 37703995

Group type: EXPERIMENTAL
Intervention: Omidubicel-onlv
Number of subjects: 108
Study: 37704387

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) system
Number of subjects: 29771

Group type: COMPARATOR
Intervention: Dismissed CDS recommendations
Number of subjects: 29771
Study: 37704438

Group type: EXPERIMENTAL
Intervention: Unilateral anterior quadratus lumborum block (30 mL of ropivacaine 0.375%)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sham block (normal saline)
Number of subjects: 88
Study: 37704499

Group type: EXPERIMENTAL
Intervention: Second booster doses of monovalent COVID-19 vaccines (AZD1222, Ad26.COV2.S, CoronaVac, BNT162b2)
Number of subjects: 30272

Group type: EXPERIMENTAL
Intervention: First booster doses of monovalent COVID-19 vaccines
Number of subjects: 30272

Group type: EXPERIMENTAL
Intervention: AZD1222 as second booster
Number of subjects: 30272

Group type: EXPERIMENTAL
Intervention: BNT162b2 as second booster
Number of subjects: 30272

Group type: EXPERIMENTAL
Intervention: AZD1222 as first booster
Number of subjects: 30272

Group type: EXPERIMENTAL
Intervention: BNT162b2 as first booster
Number of subjects: 30272
Study: 37704533

Group type: EXPERIMENTAL
Intervention: CESAR© intervention (training course for community pharmacists and smoking cessation service)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: CESAR© intervention
Number of subjects: 800
Study: 37704534

Group type: EXPERIMENTAL
Intervention: Pharmacotherapeutic Follow-up Program (6 months)
Number of subjects: 123
Study: 37704579

Group type: EXPERIMENTAL
Intervention: Luspatercept therapy
Number of subjects: 0
Study: 37704753

Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors (palbociclib) in combination with aromatase inhibitors (AI) or fulvestrant (FUL)
Number of subjects: 280
Study: 37704799

Group type: EXPERIMENTAL
Intervention: Delta variant wave
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Omicron variant wave
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Pre-Delta variant wave
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Omicron cluster positives
Number of subjects: 160
Study: 37704916

Group type: EXPERIMENTAL
Intervention: Peroxide-containing whitening toothpastes
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control/conventional toothpaste
Number of subjects: 199
Study: 37704942

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (two oral capsules daily for three months)
Number of subjects: 0
Study: 37704977

Group type: EXPERIMENTAL
Intervention: Uterocervical angle
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cervical length
Number of subjects: 70
Study: 37704984

Group type: EXPERIMENTAL
Intervention: Yoga for chronic pain (10 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT) for chronic pain (10 weeks)
Number of subjects: 75
Study: 37705043

Group type: EXPERIMENTAL
Intervention: Remote monitoring with digital sensors measuring fat mass using Withing's bioimpedance scale over a median of 10 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clinical Frailty Score (CFS) assessment
Number of subjects: 15
Study: 37705074

Group type: EXPERIMENTAL
Intervention: Mobile-based coaching intervention (WeChat mini-program) with 180 educational videos for 6 months and standard treatment
Number of subjects: 820

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 820
Study: 37705093

Group type: EXPERIMENTAL
Intervention: Science of Service Laboratory (SSL) implementation strategy
Number of subjects: 10
Study: 37705105

Group type: EXPERIMENTAL
Intervention: COVID-related impacts on interpersonal conflict
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: COVID-related impacts on employment
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: COVID-related impacts on infection exposure
Number of subjects: 188
Study: 37705327

Group type: EXPERIMENTAL
Intervention: Mezigdomide (0.4-3.2 mg single oral doses)
Number of subjects: 64

Group type: COMPARATOR
Intervention: High-fat meal
Number of subjects: 64

Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI)
Number of subjects: 64
Study: 37705369

Group type: EXPERIMENTAL
Intervention: Hybrid approach using drug-eluting stent (DES) and drug-coated balloon (DCB)
Number of subjects: 106
Study: 37705424

Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa 20 mg/kg body weight, single intravenous dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa in anti-alglucosidase alfa-negative participants (n = 12)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa in anti-alglucosidase alfa-positive participants (n = 7)
Number of subjects: 20
Study: 37705497

Group type: EXPERIMENTAL
Intervention: Zanubrutinib as second-line treatment
Number of subjects: 112
Study: 37705972

Group type: EXPERIMENTAL
Intervention: Rituximab combined with daratumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monoclonal antibodies (including rituximab and abatacept)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Steroids
Number of subjects: 0
Study: 37706025

Group type: EXPERIMENTAL
Intervention: Wharton Jelly-derived Mesenchymal Stromal Cells (WJ-MSCs) - 1 intravenous infusion of 1 × 10
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 37706171

Group type: EXPERIMENTAL
Intervention: Cutaneous vibrotactile stimulation of the hand
Number of subjects: 14

Group type: COMPARATOR
Intervention: Muscle stimulation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 14
Study: 37706457

Group type: EXPERIMENTAL
Intervention: Auricular Point Acupressure (APA) treatment administered by nurses for 3 days, with patients instructed to stimulate the points 3 times per day for 3 minutes each time.
Number of subjects: 33
Study: 37706527

Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 37706580

Group type: EXPERIMENTAL
Intervention: ATG-targeted dosing strategy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional fixed ATG dose (historical control)
Number of subjects: 66
Study: 37706671

Group type: EXPERIMENTAL
Intervention: BFR training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-BFR training
Number of subjects: 28
Study: 37706686

Group type: EXPERIMENTAL
Intervention: Psychologically informed video series
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37707290

Group type: EXPERIMENTAL
Intervention: FeNO measurements
Number of subjects: 49
Study: 37707316

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37707361

Group type: EXPERIMENTAL
Intervention: Multi-Component Strengths-Building Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 0
Study: 37707375

Group type: EXPERIMENTAL
Intervention: SRC regions
Number of subjects: 20
Study: 37707401

Group type: EXPERIMENTAL
Intervention: Deep Learning (DL) 50%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Deep Learning (DL) 75%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-Deep Learning (non-DL)
Number of subjects: 20
Study: 37707465

Group type: EXPERIMENTAL
Intervention: Strength at Home-Parents (SAHP) intervention; delivered using synchronous video technology
Number of subjects: 0
Study: 37707478

Group type: EXPERIMENTAL
Intervention: Exercise intervention (14-week supervised cardiovascular, resistance, and flexibility training, 2 group and 1 individual session per week)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Exercise intervention (14-week supervised cardiovascular, resistance, and flexibility training)
Number of subjects: 58
Study: 37707506

Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (RT) at 60-70Gy in 2 Gy fractions
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (RT)
Number of subjects: 49
Study: 37707508

Group type: EXPERIMENTAL
Intervention: High-resistance inspiratory muscle strength training (IMST)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 35
Study: 37707673

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan subcutaneous self-administration (twice or three times weekly or every 3 days) for an additional 48 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan subcutaneous self-administration
Number of subjects: 64
Study: 37707701

Group type: EXPERIMENTAL
Intervention: Biosimilar liraglutide (Melitide)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study: 37707764

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37707791

Group type: COMPARATOR
Intervention: Durvalumab (anti-PD-L1) monotherapy
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Durvalumab plus oleclumab (anti-CD73)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Durvalumab plus monalizumab (anti-NKG2A)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Durvalumab plus danvatirsen (anti-STAT3 antisense oligonucleotide)
Number of subjects: 83
Study: 37707811

Group type: EXPERIMENTAL
Intervention: Radiotherapy alone without breast surgery
Number of subjects: 31
Study: 37707817

Group type: EXPERIMENTAL
Intervention: High-dose trivalent influenza vaccine
Number of subjects: 3094

Group type: COMPARATOR
Intervention: Standard-dose quadrivalent influenza vaccine
Number of subjects: 3094

Group type: EXPERIMENTAL
Intervention: ILI activity increase by 1%
Number of subjects: 3094
Study: 37707820

Group type: EXPERIMENTAL
Intervention: Individualized stereotactic ablative radiotherapy (SABR) with doses ranging from 25 Gy in 1 fraction for peripheral tumors (0-10 cm3) to 60 Gy in 8 fractions for central tumors (>30 cm3).
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Individualized stereotactic ablative radiotherapy (SABR)
Number of subjects: 217
Study: 37707822

Group type: EXPERIMENTAL
Intervention: Omitting individualized pretest counseling and posttest counseling for those without pathogenic variants during remote genetic testing.
Number of subjects: 3839

Group type: COMPARATOR
Intervention: Control arm with pretest and/or posttest genetic counseling.
Number of subjects: 3839
Study: 37707942

Group type: COMPARATOR
Intervention: Control arm received daily walk step reminders to walk at least 5000 steps per day
Number of subjects: 41
Study: 37707944

Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioral Therapy (iCBT) with Virtual Reality Exposure Therapy (VRET) - 14-week program including 9 web-based modules and 5 individual counseling sessions (2 VRET sessions)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Waitlist Control (WLC) group
Number of subjects: 329
Study: 37707948

Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive intervention (JITAI) with 5-6 messages per week
Number of subjects: 36

Group type: COMPARATOR
Intervention: No messages from the mobile app
Number of subjects: 36
Study: 37707956

Group type: EXPERIMENTAL
Intervention: Circulating extracellular vesicles (EVs) from patients with heart failure and cardiorenal syndrome (HF-CRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EV-RNAs from HF-CRS patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibitors and mimics of miRNAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma EVs from patients with CRS
Number of subjects: 0
Study: 37708435

Group type: EXPERIMENTAL
Intervention: Mobile health application designed to increase AUD treatment engagement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 60
Study: 37708502

Group type: EXPERIMENTAL
Intervention: Routine education plus video education (intervention)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine discharge education (control)
Number of subjects: 200
Study: 37708528

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (17-g dose by mouth on postoperative day 1)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Docusate sodium (100 mg starting the day of surgery and continued twice daily at home)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Number of subjects: 2

Group type: COMPARATOR
Intervention: Docusate sodium
Number of subjects: 2
Study: 37708629

Group type: EXPERIMENTAL
Intervention: Apalutamide plus androgen-deprivation therapy (ADT)
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Apalutamide plus ADT
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 1052
Study: 37708699

Group type: EXPERIMENTAL
Intervention: MC1R risk information (average, higher)
Number of subjects: 463
Study: 37708904

Group type: EXPERIMENTAL
Intervention: NALIRIFOX
Number of subjects: 770

Group type: COMPARATOR
Intervention: nab-paclitaxel and gemcitabine
Number of subjects: 770
Study: 37708911

Group type: EXPERIMENTAL
Intervention: D-RVd (daratumumab + lenalidomide + bortezomib + dexamethasone)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: D-RVd
Number of subjects: 207

Group type: COMPARATOR
Intervention: RVd
Number of subjects: 207
Study: 37708912

Group type: EXPERIMENTAL
Intervention: Surgery plus HIPEC (100 mg/m²)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 245
Study: 37709198

Group type: EXPERIMENTAL
Intervention: Neuraxial labor analgesia (NLA)
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: Alternative approaches for labor analgesia
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: Delivery in level I units
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: Neuraxial labor analgesia (NLA) during CD
Number of subjects: 1885

Group type: COMPARATOR
Intervention: NLA vs no NLA
Number of subjects: 1885

Group type: COMPARATOR
Intervention: Scheduled vs non-scheduled CD
Number of subjects: 1885
Study: 37709280

Group type: EXPERIMENTAL
Intervention: Dexamethasone 24 mg + placebo (DX1)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Dexamethasone 24 mg + dexamethasone 24 mg (DX2)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study: 37709304

Group type: EXPERIMENTAL
Intervention: Diabetes identification using fasting glucose, HbA1c, OGTT results, or history of pre-existing diabetes.
Number of subjects: 11700

Group type: COMPARATOR
Intervention: Repeat tests for individuals identified with diabetes and a random selection of controls.
Number of subjects: 11700

Group type: EXPERIMENTAL
Intervention: Follow-up for 1 year after enrollment.
Number of subjects: 11700
Study: 37709305

Group type: EXPERIMENTAL
Intervention: ACT for informal caregiver (ACT-IC) intervention delivered over a 9-week period consisting of a collaborative goal-setting session, nine online ACT modules, nine telephone-based motivational coaching sessions and 6 monthly booster sessions following the main intervention period.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ACT for informal caregiver (ACT-IC) intervention
Number of subjects: 30
Study: 37709311

Group type: EXPERIMENTAL
Intervention: 125 mg of oral vancomycin every 6 hours for 10 days
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 37709314

Group type: EXPERIMENTAL
Intervention: nCRT + immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: nCRT
Number of subjects: 0
Study: 37709319

Group type: EXPERIMENTAL
Intervention: SGA and preterm birth
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: SGA and term/post-term birth
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Appropriate-for-gestational-age/large-for-gestational-age and preterm birth
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: History of prior child deaths
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Being a twin or triplet
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Births at health posts/clinics or in hospital
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Births on the way to facilities or outdoors
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Maternal height <145 cm
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Maternal height 145-150 cm
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Four or more antenatal care visits
Number of subjects: 40119

Group type: EXPERIMENTAL
Intervention: Education >5 years
Number of subjects: 40119
Study: 37709320

Group type: EXPERIMENTAL
Intervention: Intravenous sivelestat sodium for up to 7 days
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo for up to 7 days
Number of subjects: 238
Study: 37709324

Group type: EXPERIMENTAL
Intervention: Voice-based digital health interventions for managing diabetes distress (DD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Questionnaires assessing socio-demographics, diabetes management, e-Health literacy, and diabetes distress
Number of subjects: 20
Study: 37709327

Group type: EXPERIMENTAL
Intervention: Telemedicine (telephone consultations)
Number of subjects: 125

Group type: COMPARATOR
Intervention: In-person consultation
Number of subjects: 125
Study: 37709336

Group type: EXPERIMENTAL
Intervention: Rock climbers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-athlete control group
Number of subjects: 0
Study: 37709337

Group type: EXPERIMENTAL
Intervention: Powdered meal replacement (PMR) group: replacing morning and afternoon snacks daily with a PMR for 12 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (CON): maintaining usual diet for 12 weeks
Number of subjects: 88
Study: 37709339

Group type: EXPERIMENTAL
Intervention: Time to surgery after COVID-19 diagnosis
Number of subjects: 0
Study: 37709338

Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-CD control subjects
Number of subjects: 0
Study: 37709527

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥30 kg/m²)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Non-obese patients
Number of subjects: 431
Study: 37709550

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 60
Study: 37709661

Group type: EXPERIMENTAL
Intervention: BI 1015550 (9 mg or 18 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37709944

Group type: EXPERIMENTAL
Intervention: Snacking frequency and quality (measured by snack diet index - SDI)
Number of subjects: 1002
Study: 37709952

Group type: EXPERIMENTAL
Intervention: Height/weight-adjusted spinal bupivacaine
Number of subjects: 112

Group type: COMPARATOR
Intervention: Height-adjusted spinal bupivacaine
Number of subjects: 112
Study: 37709984

Group type: EXPERIMENTAL
Intervention: NSPT + LLLT
Number of subjects: 0

Group type: COMPARATOR
Intervention: NSPT (Sham)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy (Control)
Number of subjects: 0
Study: 37709999

Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy (MDMA-AT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo with therapy
Number of subjects: 104
Study: 37710000

Group type: EXPERIMENTAL
Intervention: Model-based reinforcement learning (RL-DITR)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard clinical methods and other deep learning models
Number of subjects: 16
Study: 37710001

Group type: EXPERIMENTAL
Intervention: Amivantamab plus lazertinib
Number of subjects: 45
Study: 37710005

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel) as second-line therapy
Number of subjects: 62
Study: 37710085

Group type: EXPERIMENTAL
Intervention: diluted thrombin time (dTT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ecarin-based chromogenic assay (ECA-II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: UPLC-MS (reference method)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: dTT and ECA-II assays
Number of subjects: 60
Study: 37710178

Group type: EXPERIMENTAL
Intervention: Hospital-based follow-up
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Primary care service follow-up
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Achievement of blood pressure targets
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Achievement of LDL-cholesterol goals
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Achievement of HbA1c-goal in patients with diabetes
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Non-smoking status
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Healthy diets
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Physical activity
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Use of acetylsalicylic acid
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Use of lipid lowering therapy
Number of subjects: 1434
Study: 37710194

Group type: EXPERIMENTAL
Intervention: Cerasmart hybrid ceramic
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Vita Enamic polymer infiltrated ceramic network (PICN) crowns
Number of subjects: 102

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 102
Study: 37710198

Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen (5 mg/day) for 5 years
Number of subjects: 810

Group type: COMPARATOR
Intervention: Radiotherapy (RT) with conventional fractions (50 Gy in 25 fractions) or hypofractionations (40.05 Gy in 15 fractions)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Overall survival and adverse effects of RT and tamoxifen
Number of subjects: 810
Study: 37710269

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated sliding hip screw (SHS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-coated lag screw thread
Number of subjects: 37
Study: 37710274

Group type: EXPERIMENTAL
Intervention: MMA embolization
Number of subjects: 722

Group type: COMPARATOR
Intervention: Conventional treatments
Number of subjects: 722